SA PRO
Free Account
Cytokinetics, IncorporatedCYTKNASDAQ
LOADING
|||
OverviewNewsFundamentalsEarningsAnalysts

Analyst Sentiment

Analysts lean bullish — 91% recommend buying.

Consensus Rating
Buy
23 analysts·High coverage
91%
Rating Distribution
Strong Buy
00%
Buy
2191%
Hold
29%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 44% higher.

Bear Case
$61.00
-3%
Consensus
$90.42
+44%
Bull Case
$136.00
+117%
Price Range23 analysts
Low
Consensus
High
$61.00
$136.00
Current Target
Current Price
$62.58
Upside to Target
$27.84

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Earnings Surprises

Recent Analyst Actions

Jan 9, 2026Jefferies
Cytokinetics (CYTK) PT Raised to $90 at Jefferies
Target:$90.00
+42.3%from $63.24
Jan 8, 2026Morgan Stanley
Cytokinetics price target raised to $90 from $71 at Morgan Stanley
Target:$90.00
+37.9%from $65.25
Dec 22, 2025Truist Financial
Cytokinetics price target raised to $84 from $70 at Truist
Target:$84.00
+24.8%from $67.33
Dec 22, 2025Morgan Stanley
Cytokinetics price target raised to $71 from $65 at Morgan Stanley
Target:$71.00
+5.4%from $67.39
Dec 22, 2025Leerink Partners
Cytokinetics price target raised to $83 from $73 at Leerink
Target:$83.00
+21.2%from $68.45
Dec 22, 2025RBC Capital
Cytokinetics price target raised to $95 from $87 at RBC Capital
Target:$95.00
+51.5%from $62.72
Dec 22, 2025Needham
Cytokinetics (CYTK) PT Raised to $84 at Needham
Target:$84.00
+21.3%from $69.25
Dec 22, 2025Goldman Sachs
Cytokinetics price target raised to $99 from $95 at Goldman Sachs
Target:$99.00
+57.8%from $62.72
Dec 22, 2025H.C. Wainwright
Cytokinetics price target raised to $136 from $120 at H.C. Wainwright
Target:$136.00
+116.8%from $62.72
Dec 22, 2025Barclays
Cytokinetics price target raised to $87 from $82 at Barclays
Target:$87.00
+38.7%from $62.72
Dec 18, 2025Goldman Sachs
Cytokinetics upgraded to Buy at Goldman on odds of ACACIA succeeding
Target:$95.00
+58.8%from $59.82
Dec 1, 2025UBS
Cytokinetics (CYTK) PT Raised to $61 at UBS
Target:$61.00
-9.3%from $67.23
Oct 6, 2025Barclays
Cytokinetics price target raised to $82 from $71 at Barclays
Target:$82.00
+43.9%from $56.97
Sep 3, 2025Evercore ISI
Cytokinetics price target raised to $80 from $60 at Evercore ISI
Target:$80.00
+60.0%from $49.99
Sep 3, 2025Barclays
Cytokinetics price target raised to $71 from $53 at Barclays
Target:$71.00
+42.0%from $49.99
Sep 2, 2025Stifel Nicolaus
Cytokinetics price target raised to $96 from $87 at Stifel
Target:$96.00
+93.5%from $49.62
Apr 24, 2025Barclays
Cytokinetics initiated with an Overweight at Barclays
Target:$55.00
+36.4%from $40.33
Mar 7, 2025Morgan Stanley
Cytokinetics assumed with an Overweight at Morgan Stanley
Target:$67.00
+54.8%from $43.27
Oct 17, 2024H.C. Wainwright
H.C. Wainwright Reiterates Buy Rating on Cytokinetics (CYTK)
Target:$120.00
+117.1%from $55.28
Sep 3, 2024Goldman Sachs
Goldman Sachs Reiterates Neutral Rating on Cytokinetics (CYTK)
Target:$60.00
+10.0%from $54.56
Jun 10, 2024Piper Sandler
Piper Sandler Reiterates Overweight Rating on Cytokinetics (CYTK)
Target:$107.00
+101.1%from $53.21
Jun 4, 2024B.Riley Financial
Cytokinetics (CYTK) PT Lowered to $92 at B.Riley
Target:$92.00
+88.9%from $48.70
May 28, 2024JMP Securities
Cytokinetics price target lowered to $78 from $106 at JMP Securities
Target:$78.00
+61.5%from $48.30
May 23, 2024H.C. Wainwright
Cytokinetics price target lowered to $90 from $94 at H.C. Wainwright
Target:$90.00
+84.8%from $48.71
May 23, 2024Needham
Cytokinetics price target lowered to $72 from $108 at Needham
Target:$72.00
+21.6%from $59.23

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance